Boehringer leads Series A of French Imchec... The Boehringer Ingelheim Venture Fund leads a financing consortium that collected €20m for French cancer therapy developer Imcheck. The Marseille-based company also presented its new CEO. … more ➔
Abivax shares jump on new Phase IIa HIV... The French biotech said that its lead therapeutic candidate demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients. Following the news, the companys … more ➔
Verona Pharma raised US-$77.8m at NASDAQ British respiratory disease specialist Verona Pharma plc (VRNA) has raised US-$77.8m (€73,96m) at NASDAQ through the issuance of 5,768,000 American Depositary Shares (ADS) – each ADS representing … more ➔
Epigenomics in €171m take-over Epigenomics and minority shareholder Cathay Fortune International Company have agreed for Cathay to take over the Berlin-based diagnostics company for €7.52 per share – a premium of almost 50%. more ➔
Euronext-listed Argenx plans €68.6m IPO...Belgian-Dutch antibody developer Argenx N.V. seeks to raise US$74.7m in a US IPO. The company, which is already listed on Euronext wants to use the proceeds to push development of its autoimmune and … more ➔
EMA backs authorisation of biologicsFour orphan drugs, three biosimilars, and one monoclonal antibody therapy have been recommended for EU market approval by the European Medicines Agencys CHMP this month. more ➔
Uniqure withdraws €1m drug Glybera from...With treatment cost of €1m+ per patient, Glybera was the most expensive therapy ever approved in Europe. Now, Uniqure has decided to terminate post-marketing studies required for prolongation of its … more ➔
GE partner Synpromics completes financing...Synthetic promoter and gene expression specialist Synpromics has completed a £5.2m (€6.2m) financing round with existing investors. more ➔
Galapagos raises US$338mAutoimmune specialist Galapagos NV (Mechelen, Belgium) has priced its 3,750,000 American Depository Shares (ADSs) in an follow-on offering led by Morgan Stanley at $90 per ADS. more ➔
Allergan and Novartis combine NASH candida...Irish Allergan and Swiss Novartis have agreed to start a proof-of-concept study of a combination of their NASH candidates cenicriviroc (Allergan) and FXR agonist LJN452 (Novartis). more ➔
